Telaprevir Receives Quick FDA Review
Share
Follow Us
The Editors at Hepatitis Central
January 25, 2011
Likely due to its ability to dramatically improve the Hepatitis C cure rate, Vertex’s telaprevir will get a priority review by the FDA.
FDA awards Vertex speedy review for hepatitis C drug
Boston Business Journal – by Julie M. Donnelly
Thursday, January 20, 2011
Vertex Pharmaceuticals Incorporated says the U.S. Food and Drug Administration has informed the company that it will make an approval decision on its drug target to treat hepatitis C by May 23rd. The FDA decided to give the company a so-called priority review for the drug, because it treats a disease where there is a high unmet medical need. This shortens the review period to six months from the usual 10 months.
Continue reading this entire article:
http://www.bizjournals.com/boston/news/2011/01/20/fda-awards-vertex-speedy-review-for.html
